Institute of Biomedical Engineering, Bogazici University, Uskudar, Istanbul, 34684, Turkey.
Department of Molecular Biology and Genetics, Halic University, Eyupsultan, Istanbul, 34060, Turkey.
Lasers Med Sci. 2024 Mar 16;39(1):91. doi: 10.1007/s10103-023-03969-x.
Investigating combined treatment methodologies is crucial for addressing the complex nature of cancer. As an emerging strategy, nano-biotechnology encourages the design of unique nanocarriers possessing simultaneous therapeutic application properties. This study aims to explore the combined effects of photodynamic and anticancer treatments using a multifunctional nanocarrier system co-administering the photosensitizer IR780 and the anticancer agent curcumin (Cur) on lung cancer cells. Nanocarriers were prepared by encapsulation IR780 and Cur inside polyethylene glycol-capped mesoporous silica nanoparticles (Cur&IR780@MSN). Various concentrations of nanocarriers were evaluated on A549 cells following 5 min NIR laser light (continuous wave, 785 nm, 500 mW/cm) irradiation. The internalization of nanocarriers was observed through the fluorescence of Cur. Changes in cell viability were determined using the MTT assay and AO/PI staining. A scratch assay analysis was also performed to examine the impact of combined treatments on cell migration. Characterization of the nanocarriers revealed adequate hydrophobic drug loading, temperature-inhibited feature, enhanced reactive oxygen species generation, a pH-dependent curcumin release profile, and high biocompatibility. Cur&IR780@MSN, which enabled the observation of synergistic treatment efficacy, successfully reduced cell viability by up to 78%. In contrast, monotherapies with curcumin-loaded nanocarriers (Cur@MSN) and IR780-loaded nanocarriers (IR780@MSN) resulted in a 38% and 56% decrease in cell viability, respectively. The constructed Cur&IR780@MSN nanocarrier has demonstrated remarkable performance in the application of combination therapies for lung cancer cells. These nanocarriers have the potential to inspire future studies in tumor treatment methods.
研究联合治疗方法对于解决癌症的复杂性至关重要。作为一种新兴策略,纳米生物技术鼓励设计具有同时治疗应用特性的独特纳米载体。本研究旨在探索使用多功能纳米载体系统联合使用光敏剂 IR780 和抗癌剂姜黄素(Cur)对肺癌细胞进行光动力和抗癌治疗的联合效应。纳米载体通过将 IR780 和 Cur 包封在聚乙二醇封端的介孔硅纳米粒子(Cur&IR780@MSN)中制备。在对 A549 细胞进行 5 分钟 NIR 激光(连续波,785nm,500mW/cm)照射后,评估了各种浓度的纳米载体。通过 Cur 的荧光观察纳米载体的内化。使用 MTT 测定法和 AO/PI 染色测定细胞活力的变化。还进行了划痕分析以检查联合治疗对细胞迁移的影响。纳米载体的特性分析表明,其具有足够的疏水性药物负载、温度抑制特性、增强的活性氧生成、pH 依赖性姜黄素释放曲线和高生物相容性。Cur&IR780@MSN 能够观察到协同治疗效果,成功地将细胞活力降低了 78%。相比之下,载有姜黄素的纳米载体(Cur@MSN)和载有 IR780 的纳米载体(IR780@MSN)的单一疗法分别导致细胞活力降低了 38%和 56%。构建的 Cur&IR780@MSN 纳米载体在肺癌细胞联合治疗中的应用中表现出显著的性能。这些纳米载体有可能激发未来肿瘤治疗方法的研究。